Kither Biotech
Laura Tasca has a diverse work experience in the scientific field. Laura recently worked as a Scientific Affairs Associate at Kither Biotech since May 2022. Prior to that, they worked as a Scientific and Teaching Tutor at XKè? Zero Tredici s.r.l. from December 2019 to May 2022, where they supported teachers and students in scientific educational laboratories.
In 2021, Laura worked as a Thesist at Università degli Studi di Torino, focusing on the optimization of a small peptide for cystic fibrosis treatment. Laura also completed a research internship at the same university in 2020, where they optimized antimicrobial candidates for superbugs through computational approaches.
Before that, Laura had research internships at RadiciGroup, where they worked on the fermentation process optimization, and at the Research Institute of Molecular Pathology (IMP) as a summer research student.
Laura's earlier experiences include a research internship and thesis work at Università degli Studi di Torino, where they studied neuronal proliferation, early neuronal differentiation, and gene function annotation. Laura also worked as a freelance author at Microbiologia Italia and as a summer research student at the Centre for Genomic Regulation (CRG).
Throughout their career, Laura has gained expertise in various scientific research areas, demonstrating their versatility and commitment to advancing scientific knowledge.
Laura Tasca earned a Laurea Magistrale LM degree in Industrial Biotechnology from Università degli Studi di Torino, which they pursued from 2018 to 2021. Prior to that, they completed their Laurea Triennale in Biotecnologie from the same university between 2014 and 2017. Laura obtained their high school diploma, known as "Diploma di maturità," from Liceo Classico Valsalice, where they studied from 2008 to 2013. Additionally, Laura obtained certifications as a Dog Trainer (Addestratore Cinofilo) in various categories from ENCI (Ente Nazionale Cinofilia Italiana) in March 2019. Laura also holds certifications in English language proficiency, including the First Certificate in English (FCE) from Cambridge English Language Assessment in 2013 and the Preliminary English Test in 2010.
This person is not in any teams
Kither Biotech
Kither Biotech is a pharmaceutical product company that focuses its R&D activities on the development of new drugs. The R&D activities of the company mainly involve the development of new drugs to treat chronic inflammatory diseases.In recent years Kither has focused its first line of activities on the development of a small peptide(KIT2014) developed internally for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and that currently has no cure. The KIT2014 peptide was assigned the Orphan Drug designation from the European Medicines Agency. The KIT2014 compound is currently undergoing the pre-clinical phase of clinical development.Kither’s product portfolio also includes a molecule (CL27), also developed internally, that is being developed for the treatment of Chronic Obstructive Pulmonary Diseases and Allergic Asthma. The company is about to start the pre-clinical phase of development of the CL27 molecule.